Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia

R. Malo De Molina, E. M. Mortensen, Marcos Restrepo, L. A. Copeland, M. J V Pugh, Antonio R Anzueto

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright

Original languageEnglish (US)
Pages (from-to)751-757
Number of pages7
JournalEuropean Respiratory Journal
Volume36
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Chronic Obstructive Pulmonary Disease
Pneumonia
Adrenal Cortex Hormones
Mortality
Outpatients
Veterans Hospitals
Therapeutics
Regression Analysis
Incidence

Keywords

  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroids
  • Mortality
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. / Malo De Molina, R.; Mortensen, E. M.; Restrepo, Marcos; Copeland, L. A.; Pugh, M. J V; Anzueto, Antonio R.

In: European Respiratory Journal, Vol. 36, No. 4, 01.10.2010, p. 751-757.

Research output: Contribution to journalArticle

@article{f22e5d0d06f8439196acf72ff35eb07f,
title = "Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia",
abstract = "Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38{\%} were on ICS. Mortality was 9{\%} at 30 days and 16{\%} at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95{\%} CI 0.70-0.83), and 90 days (OR 0.80, 95{\%} CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright",
keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroids, Mortality, Pneumonia",
author = "{Malo De Molina}, R. and Mortensen, {E. M.} and Marcos Restrepo and Copeland, {L. A.} and Pugh, {M. J V} and Anzueto, {Antonio R}",
year = "2010",
month = "10",
day = "1",
doi = "10.1183/09031936.00077509",
language = "English (US)",
volume = "36",
pages = "751--757",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia

AU - Malo De Molina, R.

AU - Mortensen, E. M.

AU - Restrepo, Marcos

AU - Copeland, L. A.

AU - Pugh, M. J V

AU - Anzueto, Antonio R

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright

AB - Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroids

KW - Mortality

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=77957855131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957855131&partnerID=8YFLogxK

U2 - 10.1183/09031936.00077509

DO - 10.1183/09031936.00077509

M3 - Article

C2 - 20413535

AN - SCOPUS:77957855131

VL - 36

SP - 751

EP - 757

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 4

ER -